Gemcitabine based combination regimens for treatment of refractory advanced breast cancer

[1]  O. Mansour,et al.  Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study. , 2006, Journal of the Egyptian National Cancer Institute.

[2]  L. Frati,et al.  A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer , 2006, BMC Cancer.

[3]  D. Amadori,et al.  Gemcitabine and taxanes in metastatic breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  V. Michalaki,et al.  Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer. , 2005, Anticancer research.

[5]  C. Cipolla,et al.  Troponins in prediction of cardiotoxic effects. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  V. Georgoulias,et al.  Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study , 2004, Oncology.

[7]  J. O’Shaughnessy,et al.  Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. , 2004, Clinical breast cancer.

[8]  J. L. Bayo,et al.  Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial. , 2004, Seminars in oncology.

[9]  P. Sánchez‐Rovira,et al.  Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study. , 2004, Seminars in oncology.

[10]  F. Schittulli,et al.  Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. , 2004, Seminars in oncology.

[11]  M. Karamouzis,et al.  Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  R. Carlson,et al.  Goals and objectives in the management of metastatic breast cancer. , 2003, The oncologist.

[13]  G. Ritorto,et al.  Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study , 2003, Cancer Chemotherapy and Pharmacology.

[14]  W. Scheithauer,et al.  Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  M. Blackstein,et al.  Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial , 2002, Oncology.

[16]  G. Stathopoulos,et al.  Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Murad,et al.  Phase II Trial of the Use of Paclitaxel and Gemcitabine as a Salvage Treatment in Metastatic Breast Cancer , 2001, American journal of clinical oncology.

[18]  M. Espié,et al.  Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer , 2001, Oncology.

[19]  W. Scheithauer,et al.  Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Dimopoulos,et al.  Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Carmichael,et al.  The role of gemcitabine in the treatment of other tumours. , 1998, British Journal of Cancer.

[22]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[23]  H. Pinedo,et al.  The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. , 1993, British Journal of Cancer.

[24]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.